ライフサイエンスコーパス: alternative drug

1 esence of the culprit drug compared with the alternative drug.

2 rit drugs and undergo DPT to identify a safe alternative drug.

3 atients received cross-over therapy with the alternative drug (61 topotecan, 49 paclitaxel) as third-

4 Alternative drug administration schemes and variable tum

5 findings emphasize the urgency of developing alternative drugs against influenza virus infection.

6 A multifaceted intervention, including alternative drug and other therapies for depression and

7 sistance and reinforces the need to evaluate alternative drugs and strategies for the control of mala

8 ve been developed using different platforms, alternative drugs, and either more biocompatible durable

9 roval of tolvaptan, safer and more effective alternative drugs are clearly needed to slow disease pro

10 dy, a number of patients crossed over to the alternative drug as third-line therapy, ie, from paclita

11 ures of T. cruzi CYP51 in complexes with two alternative drug candidates, pyridine derivatives (S)-(4

12 cleotides, and therapeutic cells, as well as alternative drug carriers such as nanoparticles.

13 ons from the Malaria in Pregnancy Preventive Alternative Drugs clinical trial.

14 To date, data from randomized trials of alternative drug coatings are lacking.

15 mum inhibitory concentration, MIC) when this alternative drug combination regimen was used.

16 by drug-resistant leprosy shows the need for alternative drug combinations and shorter, safer regimen

17 in children, including improved techniques, alternative drug combinations, as well as prospective in

18 f SH2 via the coiled-coil domain (CCD) is an alternative drug design strategy.

19 Therefore, alternative drug development strategies are needed to im

20 ERalpha via the ERalpha/14-3-3 complex as an alternative drug discovery approach.

21 few data exist on the cost effectiveness of alternative drug-eluting stent (DES) designs.

22 s that reduce coronary restenosis, including alternative drug-eluting stent platforms.

23 Supraflex seems a safe and effective alternative drug-eluting stent to other stents in clinic

24 0.29%-1.19%]) compared with those receiving alternative drug-eluting stents.

25 in declined, confirming the utility of these alternative drugs for enteric fever treatment.

26 Risks associated with alternative drugs in the same class, including clarithro

27 Here, we explore an alternative, drug-induced mechanism that impedes therape

28 ational states of full-length Src, including alternative drug-inhibited forms.

29 s, is unsuitable for mass administration, an alternative drug is needed urgently.

30 The selection of structurally different alternative drugs is important to avoid recurrence.

31 t further research is in progress to explore alternative drugs, optimized dosing and duration, and im

32 ciousness, optimised stimulation parameters, alternative drugs, or rehabilitation strategies still ne

33 Therefore, identifying alternative drug regimens is a pressing priority.

34 , etc.), extrarenal allograft recipients, or alternative drug regimens such as steroid or MMF elimina

35 n AR-negative prostate cancer may provide an alternative drug target for prostate cancer patients pro

36 otential use of correlated reaction sets for alternative drug target identification.

37 Jun N-terminal protein kinase 1 (JNK1) as an alternative drug target in the distal BCR pathway.

38 surfaced exposed pocket on the AR-DBD as an alternative drug-target site for AR inhibition.

39 tive allosteric sites as good candidates for alternative drug targeting.

40 ity of patients with this cancer; therefore, alternative drug targets, including epigenetic enzymes,

41 ighlighting relevant drug-drug interactions, alternative drugs that can be safely used are suggested.

42 need for infusion of coagulation factors (or alternative drugs that promote coagulation), and may the

43 Alternative drugs that target bacterial virulence withou

44 These could become the targets of future alternative drug therapies to slow down the spread of an

45 to guide modelling and simulation to predict alternative drug therapies.

46 nciclovir-resistant strains disappeared with alternative drug therapy.

47 d potentially benefit from a reduced dose or alternative drug to reduce the risk of ADRs.

48 ihydroartemisinin-piperaquine is a promising alternative drug to replace sulfadoxine-pyrimethamine fo

49 MIs are under development as alternative drugs to augment current antiretroviral ther

50 tle information about the efficacy of active alternative drugs to carbapenems except beta-lactam/beta

51 nostic measures, potential cross-reactivity, alternative drugs to prescribe, and where more detailed

52 Because of the atypical demographics and the alternative drug use patterns, this young population of

53 etic overlap between diseases and predicting alternative drug use.

54 etic overlap between diseases and predicting alternative drug use.Computation can also be used to mod

55 Alternative drug-use strategies such as mixing, in which

56 reased efforts should be made to ensure that alternative drugs will be available for prevention of ma